Literature DB >> 18484616

Regulation of sinusoidal perfusion in portal hypertension.

Hendrik Reynaert1, Daniel Urbain, Albert Geerts.   

Abstract

Portal hypertension, a major complication of cirrhosis, is caused by both increased portal blood flow and augmented intrahepatic vascular resistance. Even though the latter is primarily caused by anatomical changes, it has become clear that dynamic factors contribute to the increased hepatic vascular resistance. The hepatic sinusoid is the narrowest vascular structure within the liver and is the principal site of blood flow regulation. The anatomical location of hepatic stellate cells, which embrace the sinusoids, provides a favorable arrangement for sinusoidal constriction, and for control of sinusoidal vascular tone and blood flow. Hepatic stellate cells possess the essential contractile apparatus for cell contraction and relaxation. Moreover, the mechanisms of stellate cell contraction are better understood, and many substances which influence contractility have been identified, providing a rationale and opportunity for targeting these cells in the treatment of portal hypertension in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18484616     DOI: 10.1002/ar.20669

Source DB:  PubMed          Journal:  Anat Rec (Hoboken)        ISSN: 1932-8486            Impact factor:   2.064


  21 in total

1.  Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats.

Authors:  Jiqiao Liu; Liping Peng; Juan Yang; Min Wang; Shengnan Xu; Jingmei Liu; Ping Han; Jiayi He; Dean Tian; Qi Zhou
Journal:  Dig Dis Sci       Date:  2015-02-28       Impact factor: 3.199

Review 2.  Hepatic stellate cells--the pericytes in the liver.

Authors:  Claus Hellerbrand
Journal:  Pflugers Arch       Date:  2013-01-05       Impact factor: 3.657

Review 3.  Current status and perspectives of immune-based therapies for hepatocellular carcinoma.

Authors:  Maridi Aerts; Daphné Benteyn; Hans Van Vlierberghe; Kris Thielemans; Hendrik Reynaert
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 4.  Mechanisms of adaptation of the hepatic vasculature to the deteriorating conditions of blood circulation in liver cirrhosis.

Authors:  Dmitry Victorovich Garbuzenko; Nikolay Olegovich Arefyev; Dmitry Vladimirovich Belov
Journal:  World J Hepatol       Date:  2016-06-08

Review 5.  Serelaxin in clinical development: past, present and future.

Authors:  Elaine Unemori
Journal:  Br J Pharmacol       Date:  2017-01-29       Impact factor: 8.739

6.  Establishment and characterization of an immortalized rat hepatic stellate cell line.

Authors:  Tao Li; Xi-Sheng Leng; Ji-Ye Zhu; Fu-Shun Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

7.  Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis.

Authors:  Xuelian Xiong; Henry Kuang; Sahar Ansari; Tongyu Liu; Jianke Gong; Shuai Wang; Xu-Yun Zhao; Yewei Ji; Chuan Li; Liang Guo; Linkang Zhou; Zhimin Chen; Paola Leon-Mimila; Meng Ting Chung; Katsuo Kurabayashi; Judy Opp; Francisco Campos-Pérez; Hugo Villamil-Ramírez; Samuel Canizales-Quinteros; Robert Lyons; Carey N Lumeng; Beiyan Zhou; Ling Qi; Adriana Huertas-Vazquez; Aldons J Lusis; X Z Shawn Xu; Siming Li; Yonghao Yu; Jun Z Li; Jiandie D Lin
Journal:  Mol Cell       Date:  2019-08-08       Impact factor: 17.970

Review 8.  Liver regeneration biology: Implications for liver tumour therapies.

Authors:  Christopher Hadjittofi; Michael Feretis; Jack Martin; Simon Harper; Emmanuel Huguet
Journal:  World J Clin Oncol       Date:  2021-12-24

9.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

10.  Potential drug mechanism(s) targeting the contractile status of hepatic stellate cells.

Authors:  Claudio Bucolo; Filippo Drago; Salvatore Salomone
Journal:  Front Pharmacol       Date:  2012-10-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.